Janupil 100mg Tablet contains Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin works by enhancing the levels of incretin hormones, which increase insulin release from pancreatic beta cells and decrease glucagon secretion from alpha cells in a glucose-dependent manner. This mechanism helps improve glycemic control without causing significant hypoglycemia. Janupil is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dosage is 100 mg once daily, administered orally with or without food. Janupil is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis and should be used cautiously in patients with renal impairment, with dose adjustments as necessary. Common adverse effects include nasopharyngitis, headache, and upper respiratory tract infections. Rarely, serious side effects such as pancreatitis and hypersensitivity reactions may occur. Regular monitoring of blood glucose levels and renal function is advised during therapy to ensure safety and efficacy. Janupil 100mg offers a well-tolerated option for improving glycemic control in type 2 diabetes patients.